Control of Apollo
Sibannac owns 51% of Apollo Wellness Centers, Inc. That majority interest gives Sibannac the controlling position in the joint venture. Doc-Rx is Sibannac's partner in Apollo; Sibannac has not acquired Doc-Rx.
At a glance
The joint venture in brief.
- Joint venture
- Apollo Wellness Centers, Inc.
- Partners
- Sibannac, Inc. (SNNC) and Doc-Rx.com, LLC
- Agreement date
- October 1, 2026
- Sibannac's interest
- 51% (majority interest in Apollo Wellness)
- Revenue
- Revenue terms are set out in the joint venture agreement
- Main growth plan
- Standing up wellness clinics under the Apollo Wellness Centers brand, licensed to and owned by licensed prescribers
- Platform
- Doc-Rx telehealth, partner 503A compounding pharmacies, U.S.-made peptides and health tracking, for licensed professional use
For shareholders
What Sibannac shareholders now own.
Through its majority stake, Sibannac controls a new business in medically supervised wellness care that does not have to build its foundation from scratch.
An operating platform from day one
Apollo is built on the platform Doc-Rx already runs: secure telehealth for patients and clinicians, partner 503A compounding pharmacies, peptides made in the U.S. from raw material to finished product, and health tracking. All of it is for licensed professional use.
Revenue terms in the agreement
The joint venture agreement sets out how Apollo is to earn revenue. The venture begins with its business terms already in place, alongside a working platform.
The main growth plan: Apollo Wellness Centers
Apollo expects its largest source of revenue to be standing up wellness clinics under the Apollo Wellness Centers brand. Each clinic would be owned by a licensed prescriber who licenses the Apollo Wellness Centers brand and orders through Doc-Rx. The model is intended to let the brand grow without the joint venture owning each location.
How it works
Made in the U.S., documented batch by batch.
Doc-Rx works with partner compounding pharmacies that keep each step of making their peptides inside the United States. Apollo plans to supply its locations from that chain.
Certified cGMP Facility
Documented, controlled manufacturing processes designed for batch consistency, traceability, and release discipline.
Manufactured in the United States
Synthesis, fill, and domestic dispatch — no overseas trans-shipment ambiguity. Built for licensed professionals who need clear U.S. provenance.
Certified cGMP facility
Produced under current Good Manufacturing Practice controls: batch records, process documentation, and quality oversight from synthesis through fill.
>99% purity standard
Each lot targets greater than 99% purity by HPLC analysis before it is released.
Accredited U.S. laboratory testing
Identity and purity are verified by accredited laboratories in the United States. Independent analytics, not marketing claims alone.
Certificate of Analysis on every batch
Each production batch ships with a COA covering identity/purity verification so prescribers and clinics have lot-level documentation on file.
QR code on every vial → batch COA
Scan the QR code on the vial to open the Certificate of Analysis for that exact batch — instant lot traceability at the point of care.
>99%HPLC purity target
cGMPU.S. facility standard
COAIssued every batch
QROn every vial
Planned Apollo product line
In development. The joint venture intends to add Apollo-branded products over time.
Peptides
An Apollo line of U.S.-made peptide formulations.
Nutraceuticals
Supplements developed to complement care at Apollo locations.
Medical foods
Specially formulated foods for use under the supervision of a physician.
Telemedicine
Full telemedicine consults and asynchronous visits with licensed clinicians.
The partners
Two companies behind Apollo Wellness.
Sibannac
A holding company developing alternative wellness products and experiences, building brands in health and wellness.
Doc-Rx
Doc-Rx created the platform Apollo is built on: telehealth, partnerships with U.S.-based 503A compounding pharmacies, U.S.-made peptides and health tracking, for licensed professional use.
The platform
Doc-Rx: care online, filled and shipped
Doc-Rx describes its service as HIPAA-protected telehealth: patients and clinicians meet securely online, licensed clinicians prescribe, and prescriptions go to FDA-registered pharmacy fulfillment and ship across the U.S. The platform also includes health tracking, and it is built for licensed professional use.
Visit doc-rx.comFollow Sibannac's progress
Sibannac, Inc. trades under the symbol SNNC. Filings, news and investor information are at snncinc.com/investors. Investor relations:
investors@sibannacinc.comForward-Looking Statements
This page contains forward-looking statements. They include statements about the plans, objectives, expected activities and benefits of Apollo Wellness Centers, Inc. and its joint venture partners, Sibannac, Inc. and Doc-Rx.com, LLC. Examples are plans to stand up wellness clinics under the Apollo Wellness Centers brand through a licensing model; the expectation that these clinics will be the joint venture's largest source of revenue; the revenue the joint venture expects to earn under its agreement; and plans to develop an Apollo line of peptides, nutraceuticals and medical foods. Words such as "plans," "intends," "expects," "aims," "designed to," "will" and similar expressions identify forward-looking statements.
These statements are based on current expectations and assumptions. They are not guarantees of future results, and actual results may differ materially. Factors that could cause differences include: the joint venture's ability to find and retain licensed prescribers to own and operate clinics, and to open clinics on the expected timeline or at all; whether the joint venture generates the revenue contemplated by its agreement, or any revenue or profit, and how much of any benefit accrues to Sibannac; the terms of the joint venture agreement, including Doc-Rx's rights as minority partner; Sibannac's ability to meet its obligations to the joint venture, including any funding; franchise, business opportunity and licensing laws that may apply to the licensing model; reliance on Doc-Rx's platform and on the independent compounding pharmacies it partners with, including the accuracy of the manufacturing, testing and quality information they provide; federal and state laws governing compounding pharmacies, the practice of medicine and peptide products, including any change in how the FDA or state authorities treat particular peptides; the need for additional capital; competition; and the other risks described in Sibannac's disclosure statements and reports posted on OTC Markets (otcmarkets.com).
Information on this page about manufacturing, testing, purity and batch documentation is provided by Doc-Rx.com, LLC and its partner compounding pharmacies. Forward-looking statements speak only as of October 27, 2026. Except as required by law, Sibannac undertakes no obligation to update or revise any forward-looking statement. This page is for information only and is not an offer to sell, or a solicitation of an offer to buy, any securities.